South Dakota Investment Council Increases Holdings in Emergent Biosolutions Inc (NYSE:EBS)

South Dakota Investment Council increased its stake in shares of Emergent Biosolutions Inc (NYSE:EBS) by 21.3% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 9,700 shares of the biopharmaceutical company’s stock after acquiring an additional 1,700 shares during the quarter. South Dakota Investment Council’s holdings in Emergent Biosolutions were worth $469,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in EBS. Clarus Wealth Advisors increased its stake in Emergent Biosolutions by 30.7% during the second quarter. Clarus Wealth Advisors now owns 2,114 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 496 shares during the last quarter. KBC Group NV acquired a new stake in shares of Emergent Biosolutions in the second quarter valued at $126,000. Marshall Wace North America L.P. grew its stake in shares of Emergent Biosolutions by 250.5% in the first quarter. Marshall Wace North America L.P. now owns 4,700 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 3,359 shares in the last quarter. Connable Office Inc. acquired a new stake in shares of Emergent Biosolutions in the second quarter valued at $262,000. Finally, Royce & Associates LP acquired a new stake in shares of Emergent Biosolutions in the first quarter valued at $285,000. Hedge funds and other institutional investors own 88.78% of the company’s stock.

In related news, Director Kathryn C. Zoon sold 1,509 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $56.12, for a total transaction of $84,685.08. Following the completion of the transaction, the director now directly owns 21,494 shares of the company’s stock, valued at approximately $1,206,243.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 14.10% of the company’s stock.



EBS has been the subject of a number of research reports. Laidlaw set a $72.00 price objective on Emergent Biosolutions and gave the company a “buy” rating in a research note on Wednesday, September 4th. Wells Fargo & Co raised Emergent Biosolutions from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $61.00 to $64.00 in a research note on Wednesday, September 4th. Chardan Capital set a $71.00 price objective on Emergent Biosolutions and gave the company a “buy” rating in a research note on Tuesday, September 3rd. ValuEngine raised Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Wednesday, September 4th. Finally, Guggenheim initiated coverage on Emergent Biosolutions in a research note on Thursday. They issued a “buy” rating and a $65.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Emergent Biosolutions currently has an average rating of “Buy” and an average target price of $70.25.

EBS traded down $1.55 on Friday, hitting $52.59. 188,298 shares of the company were exchanged, compared to its average volume of 504,523. Emergent Biosolutions Inc has a twelve month low of $39.11 and a twelve month high of $73.89. The company has a market cap of $2.79 billion, a price-to-earnings ratio of 22.57, a price-to-earnings-growth ratio of 0.93 and a beta of 1.56. The company has a current ratio of 2.30, a quick ratio of 1.53 and a debt-to-equity ratio of 0.84. The firm has a 50-day moving average price of $45.43 and a two-hundred day moving average price of $48.00.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $0.12 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by ($0.04). Emergent Biosolutions had a positive return on equity of 6.68% and a negative net margin of 2.04%. The company had revenue of $243.20 million for the quarter, compared to analyst estimates of $217.94 million. During the same period in the previous year, the firm earned $1.07 earnings per share. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. Equities analysts expect that Emergent Biosolutions Inc will post 3.06 EPS for the current year.

Emergent Biosolutions Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

See Also: Why are trading ranges significant?

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.